The clinical benefits provided by trimetazidine (Vastarel® MR) in left ventricular dysfunction patients

Research output: Contribution to journalArticlepeer-review

Abstract

Metabolic treatment involves the use of drugs that improve cardiomyocyte function. Trimetazidine (Vastarel® MR) is the most investigated drug in this group with a well-established role in the treatment of chronic angina. The available data suggest that therapy combining trimetazidine and hemodynamic drugs is effective in patients with chronic heart failure, leading to additional benefits such as improvement in left ventricular function, exercise tolerance and quality of life. However, while trimetazidine has shown beneficial effects on surrogate endpoints in several small trials, its effect on cardiovascular events in chronic heart failure subjects needs to be confirmed in further large randomized studies.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalHeart and Metabolism
Issue number49
Publication statusPublished - 2011

Keywords

  • Chronic heart failure
  • Left ventricular function
  • Metabolic therapy
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'The clinical benefits provided by trimetazidine (Vastarel® MR) in left ventricular dysfunction patients'. Together they form a unique fingerprint.

Cite this